Status:
UNKNOWN
Cerebral Magnetic Resonance Spectroscopy at Term Corrected Age and Dysexecutive Syndrome in Very Preterm Children at 5.5-years-old
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Preterm Birth
Eligibility:
All Genders
66-66 years
Brief Summary
Background: Compared to term-born peers, very preterm children generally perform poorly in executive functions, with a significant impact on learning at school and quality of life. These EF deficits a...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Inclusion criteria form EPIPAGE2 and EPIRMEX
- Children who underwent spectroscopy with regions of interest analyzed: periventricular zone, gray nuclei, brainstem.
- Children who received a complete cognitive assessment in EPIRMEX (integrated assessment identical to that planned in EPIPAGE2) at age 5 ½.
- Non-inclusion Criteria:
- Children with severe karyotype abnormalities.
- Children with central nervous system malformations diagnosed antenatally or on neonatal tests
- Children with severe cerebral palsy or major neurosensory (blindness, profound deafness...) not allowing children to take the tests scheduled at age 5 ½.
Exclusion
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT06055062
Start Date
October 1 2023
End Date
December 1 2023
Last Update
September 26 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.